Atrix/Sanofi Eligard Monthly Could Launch In Advance Of 3-Month Version
Atrix and Sanofi-Synthelabo may launch the monthly formulation of their prostate cancer therapy Eligard before the approval of the three-month formulation, which is pending at FDA, Atrix said following the Jan. 23 approval of leuprolide 7.5 mg
You may also be interested in...
A Department of Justice investigation into AstraZeneca's Zoladex marketing practices is continuing following the recent settlement with TAP over Lupron.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials